AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20605942 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent expansions of child verbal utterances
Number of subjects: 32
Study 20605942 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrics representing the number of parent utterances following into the child's focus of attention
Number of subjects: 32
Study 20605942 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrics representing the number of parent utterances responding to child verbal communication acts
Number of subjects: 32
Study 19138971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification intervention group (reduced total dietary fat intake to 20% of total energy intake, increased fruit and vegetable intake to > or =5 servings/d, and grain products to > or =6 servings/d)
Number of subjects: 48835
Study 19138971 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific dietary modification mentioned)
Number of subjects: 48835
Study 19138971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification intervention
Number of subjects: 48835
Study 16367858 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative material applied in test subjects
Number of subjects: 122
Study 16367858 — intervention group
Group type: COMPARATOR
Intervention: Omitted regenerative material in controls
Number of subjects: 122
Study 14687987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine + prednisone (arm A: 66 patients)
Number of subjects: 133
Study 14687987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine + prednisone + IFN-alpha (arm B: 67 patients)
Number of subjects: 133
Study 14687987 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha maintenance therapy (41 patients)
Number of subjects: 133
Study 14687987 — intervention group
Group type: COMPARATOR
Intervention: Clinical observation (37 patients)
Number of subjects: 133
Study 11151453 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab as a single agent
Number of subjects: 0
Study 11151453 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with chemotherapy
Number of subjects: 0
Study 11151453 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab (combined with anthracyclines)
Number of subjects: 0
Study 8830943 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluene (100 ppm)
Number of subjects: 6
Study 8830943 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 6
Study 1567690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, lorazepam, and prochlorperazine (DLP)
Number of subjects: 84
Study 1567690 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam and prochlorperazine with placebo (LP)
Number of subjects: 84
Study 31551517 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (Bz) as part of the conditioning regimen and GvHD prophylaxis
Number of subjects: 25
Study 30565422 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual (AV) intervention during UDE
Number of subjects: 218
Study 30565422 — intervention group
Group type: COMPARATOR
Intervention: Standard UDE without AV intervention
Number of subjects: 218
Study 28347938 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination questionnaire (with or without sticky note)
Number of subjects: 13803
Study 28347938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sticky note requesting completion of the questionnaire
Number of subjects: 13803
Study 28347938 — intervention group
Group type: EXPERIMENTAL
Intervention: Different cognitive targets (anticipated regret or beneficence) in questionnaires
Number of subjects: 13803
Study 28347938 — intervention group
Group type: COMPARATOR
Intervention: Control 1 (no questionnaire)
Number of subjects: 13803
Study 28347938 — intervention group
Group type: COMPARATOR
Intervention: Control 2 (demographics questionnaire)
Number of subjects: 13803
Study 25557693 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal (240 mL, 12 kcal broth)
Number of subjects: 42
Study 25557693 — intervention group
Group type: COMPARATOR
Intervention: Control meal (water)
Number of subjects: 42
Study 24291952 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive facilitative exercise (RFE)
Number of subjects: 0
Study 24291952 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 0
Study 21936759 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who watched clips of the individual with TBI engaged in conversation
Number of subjects: 34
Study 21936759 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who listened to clips of the individual with TBI engaged in conversation
Number of subjects: 34
Study 21936759 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who viewed the individual's movements as inappropriate
Number of subjects: 34
Study 19158587 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 12
Study 19158587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 to 1 cm H2O)
Number of subjects: 12
Study 17473091 — intervention group
Group type: EXPERIMENTAL
Intervention: Head cooling for 72 hours, starting within 6 hours after birth (rectal temperature maintained at 34.5 +/- 0.5 degrees C)
Number of subjects: 218
Study 17473091 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 218
Study 15196399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuspid occlusal upheaving splint
Number of subjects: 20
Study 15196399 — intervention group
Group type: COMPARATOR
Intervention: Stabilization splint
Number of subjects: 20
Study 12529076 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey mode, n = 3,500
Number of subjects: 7000
Study 12529076 — intervention group
Group type: COMPARATOR
Intervention: U.S. mail-based survey mode, n = 3,500
Number of subjects: 7000
Study 12529076 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey mode
Number of subjects: 7000
Study 12529076 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey mode and U.S. mail-based survey mode
Number of subjects: 7000
Study 9462604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk admissions for heart failure
Number of subjects: 120
Study 9462604 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk admissions for heart failure
Number of subjects: 120
Study 8127120 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash cefuroxime (1.5 gm intravenously at anesthetic induction and again 2 hours later)
Number of subjects: 203
Study 8127120 — intervention group
Group type: COMPARATOR
Intervention: 48-hour cefuroxime (1.5 gm intravenously at anesthetic induction and again 2 hours later, then every 6 hours for 48 hours)
Number of subjects: 203
Study 8127120 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash cefuroxime
Number of subjects: 203
Study 8127120 — intervention group
Group type: COMPARATOR
Intervention: 48-hour cefuroxime
Number of subjects: 203
Study 2642873 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting time longer than 30 minutes after cleansing enema
Number of subjects: 0
Study 2642873 — intervention group
Group type: COMPARATOR
Intervention: Waiting time of 30 minutes or less after cleansing enema
Number of subjects: 0
Study 1091397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5‐mg doses of digoxin from lot 1
Number of subjects: 6
Study 1091397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5‐mg doses of digoxin from lot 2
Number of subjects: 6
Study 1091397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5‐mg doses of digoxin from lot 3
Number of subjects: 6
Study 1091397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5‐mg doses of digoxin from lot 4
Number of subjects: 6
Study 1091397 — intervention group
Group type: COMPARATOR
Intervention: 0.5‐mg doses of digoxin from one lot taken twice
Number of subjects: 6
Study 1091397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intersubject variation
Number of subjects: 6
Study 1091397 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary digoxin determinations
Number of subjects: 6
Study 31378395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (500 mg twice a day, adjustable to a maximum of four tablets and a minimum of one tablet a day)
Number of subjects: 605
Study 31378395 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two oral tablets a day)
Number of subjects: 605
Study 31378395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 605
Study 31378395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study 28514344 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium laser treatment
Number of subjects: 46
Study 28514344 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical treatment (Control)
Number of subjects: 46
Study 26101461 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine naturally enriched with resveratrol (NPVRW)
Number of subjects: 0
Study 26101461 — intervention group
Group type: COMPARATOR
Intervention: McDonald's meal (McDM)
Number of subjects: 0
Study 26101461 — intervention group
Group type: EXPERIMENTAL
Intervention: McDonald's meal (McDM) + NPVRW
Number of subjects: 0
Study 26101461 — intervention group
Group type: COMPARATOR
Intervention: Baseline (B)
Number of subjects: 0
Study 26101461 — intervention group
Group type: EXPERIMENTAL
Intervention: NPVRW
Number of subjects: 0
Study 24711627 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 1106
Study 24711627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1106
Study 24711627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1106
Study 21849549 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied over human visual cortex to induce illusory perceptions (phosphenes) at perceptual threshold.
Number of subjects: 0
Study 20329608 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electro-acupuncture (TCEA) applied for 20 min before induction and throughout the operation
Number of subjects: 60
Study 20329608 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthesia without TCEA (Control group)
Number of subjects: 60
Study 17723882 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels less than 3.0 pg/mL
Number of subjects: 54
Study 17723882 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels between 3.0-5.3 pg/mL
Number of subjects: 54
Study 17723882 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels greater than or equal to 5.3 pg/mL
Number of subjects: 54
Study 17723882 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels less than 5.5 pg/mL
Number of subjects: 54
Study 17723882 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels between 5.5-9.0 pg/mL
Number of subjects: 54
Study 17723882 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels greater than or equal to 9.0 pg/mL
Number of subjects: 54
Study 15226326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential doxorubicin followed by docetaxel (A‐‐>T)
Number of subjects: 144
Study 15226326 — intervention group
Group type: COMPARATOR
Intervention: Concomitant doxorubicin and docetaxel (AT)
Number of subjects: 144
Study 11804377 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric questionnaires for quality of life assessment
Number of subjects: 0
Study 11804377 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal studies measuring quality of life
Number of subjects: 0
Study 11804377 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised clinical trials for quality of life assessment
Number of subjects: 0
Study 11804377 — intervention group
Group type: EXPERIMENTAL
Intervention: Simpler instruments and specific training by research nurses
Number of subjects: 0
Study 9562310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid interleukin 6 (IL-6) levels in ALS patients
Number of subjects: 105
Study 9562310 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid interleukin 6 (IL-6) levels in MS and HAM patients
Number of subjects: 105
Study 9562310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid interleukin 6 (IL-6) levels in patients with and without oligoclonal bands
Number of subjects: 105
Study 9562310 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid interleukin 6 (IL-6) levels in relation to clinical disease activity in MS
Number of subjects: 105
Study 7832682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (GaAlAs laser)
Number of subjects: 71
Study 7832682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 3276193 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with 300 mg doxycycline
Number of subjects: 999
Study 3276193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 999
Study 30055163 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromechanical exoskeleton-assisted gait training
Number of subjects: 40
Study 30055163 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapist-assisted gait training
Number of subjects: 40
Study 30055163 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 40
Study 28402245 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (starting dose of 50 μg daily, or 25 μg if body weight <50 kg or with coronary heart disease)
Number of subjects: 737
Study 28402245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 737
Study 28402245 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 737
Study 25577731 — intervention group
Group type: EXPERIMENTAL
Intervention: Real images exposure (n = 14)
Number of subjects: 28
Study 25577731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper-real images exposure (n = 14)
Number of subjects: 28
Study 25577731 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 9)
Number of subjects: 28
Study 23516012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration ad libitum
Number of subjects: 0
Study 23516012 — intervention group
Group type: COMPARATOR
Intervention: No hydration
Number of subjects: 0
Study 21909121 — intervention group
Group type: EXPERIMENTAL
Intervention: nsEERPE
Number of subjects: 180
Study 21909121 — intervention group
Group type: EXPERIMENTAL
Intervention: nsEERPE with BNS
Number of subjects: 180
Study 21909121 — intervention group
Group type: COMPARATOR
Intervention: EERPE
Number of subjects: 180
Study 21909121 — intervention group
Group type: COMPARATOR
Intervention: EERPE with BNS
Number of subjects: 180
Study 19750573 — intervention group
Group type: EXPERIMENTAL
Intervention: Small sphincterotomy combined with endoscopic papillary large balloon dilation (SES + ELBD)
Number of subjects: 55
Study 19750573 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 55
Study 17540804 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 1559
Study 17540804 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 1559
Study 17540804 — intervention group
Group type: COMPARATOR
Intervention: Cotesting with cytology and HPV testing
Number of subjects: 1559
Study 17540804 — intervention group
Group type: COMPARATOR
Intervention: Hybrid Capture 2
Number of subjects: 1559
Study 16563245 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 57
Study 16563245 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (Control)
Number of subjects: 57
Study 11872052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh repair
Number of subjects: 300
Study 11872052 — intervention group
Group type: COMPARATOR
Intervention: Non-mesh repair
Number of subjects: 300
Study 10201430 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculomicrotremor readings from parkinsonian patients
Number of subjects: 22
Study 10201430 — intervention group
Group type: COMPARATOR
Intervention: Oculomicrotremor readings from normal healthy volunteers
Number of subjects: 22
Study 10201430 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication withdrawn in one patient
Number of subjects: 22
Study 7574280 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative wrist splinting for 2 weeks
Number of subjects: 40
Study 7574280 — intervention group
Group type: COMPARATOR
Intervention: Bulky dressing only
Number of subjects: 40
Study 2406296 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine toothpaste
Number of subjects: 10
Study 2406296 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% triclosan toothpaste
Number of subjects: 10
Study 2406296 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine rinse
Number of subjects: 10
Study 2406296 — intervention group
Group type: COMPARATOR
Intervention: water brushing
Number of subjects: 10
Study 7356889 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic beta‐adrenoceptor blockade with oxprenolol
Number of subjects: 0
Study 7356889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31602531 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (SR)
Number of subjects: 345
Study 31602531 — intervention group
Group type: COMPARATOR
Intervention: Proton beam therapy (PBT)
Number of subjects: 345
Study 31535099 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone block grafts fixed at a distance (BBG‐D)
Number of subjects: 30
Study 31535099 — intervention group
Group type: COMPARATOR
Intervention: Resorbable poly‐D‐L‐lactide foil fixed at a distance (SonicWeld Rx shell technique [SWST])
Number of subjects: 30
Study 28682955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate (RL)
Number of subjects: 500
Study 28682955 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 500
Study 25032942 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculation resuscitation group (nitroglycerin, enoximone, dopamine, dexamethasone)
Number of subjects: 90
Study 25032942 — intervention group
Group type: COMPARATOR
Intervention: Standard resuscitation group (fluids, noradrenaline, dobutamine, hydrocortisone)
Number of subjects: 90
Study 23238293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-PA/high-OA (HOA) diet
Number of subjects: 0
Study 23238293 — intervention group
Group type: COMPARATOR
Intervention: High-PA diet
Number of subjects: 0
Study 21814174 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible PD solutions
Number of subjects: 267
Study 21814174 — intervention group
Group type: COMPARATOR
Intervention: Conventional PD solutions
Number of subjects: 267
Study 19198801 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment (Dresden scoliosis orthosis)
Number of subjects: 90
Study 19198801 — intervention group
Group type: COMPARATOR
Intervention: Noncompliant group (no brace treatment)
Number of subjects: 90
Study 19198801 — intervention group
Group type: COMPARATOR
Intervention: Compliant group (brace treatment)
Number of subjects: 90
Study 16937304 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (estramustine phosphate + endocrine therapy)
Number of subjects: 57
Study 16937304 — intervention group
Group type: COMPARATOR
Intervention: Endocrine monotherapy
Number of subjects: 57
Study 15665929 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoblockers and angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 11221552 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9164179 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 5 micrograms/kg/d SC bolus injection
Number of subjects: 86
Study 9164179 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim 10 micrograms/kg/d SC continuous infusion
Number of subjects: 86
Study 7693314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (topical glucocorticoid)
Number of subjects: 25
Study 7693314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3297278 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with BCNU, cyclophosphamide, vincristine, and prednisone (BCVP) given every 6 weeks for an additional 18 months
Number of subjects: 111
Study 3297278 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (control group)
Number of subjects: 111
Study 31020442 — intervention group
Group type: EXPERIMENTAL
Intervention: Infographic
Number of subjects: 112
Study 31020442 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette
Number of subjects: 112
Study 31020442 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure
Number of subjects: 112
Study 31020442 — intervention group
Group type: COMPARATOR
Intervention: Mandated legislation
Number of subjects: 112
Study 30066796 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) monotherapy
Number of subjects: 48
Study 30066796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy
Number of subjects: 48
Study 30066796 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA) + Lamotrigine (LTG) polytherapy
Number of subjects: 48
Study 30066796 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA) + Levetiracetam (LEV) polytherapy
Number of subjects: 48
Study 30066796 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 48
Study 27218676 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5745 (multiple doses: 0.3, 1.0, 2.5 or 5.0 mg/kg IV every 2 weeks or 150 mg SC weekly)
Number of subjects: 74
Study 27218676 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5745 (multiple doses)
Number of subjects: 74
Study 27218676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 27218676 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5745
Number of subjects: 74
Study 27218676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders to GS-5745
Number of subjects: 74
Study 24725326 — intervention group
Group type: EXPERIMENTAL
Intervention: LipiFlow treatment
Number of subjects: 31
Study 24725326 — intervention group
Group type: COMPARATOR
Intervention: Lid-margin hygiene (combined lid warming and massage)
Number of subjects: 31
Study 23584092 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1232